

Full English text available at
www.actasdermo.org

ORIGINAL ARTICLE

Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features

J. Angel-Baldo^{a,b,*}, S. Podlipnik^{c,1}, A. Azón^a, A. Boada^d, A. Arrieta^d, J. Marcoval^e, C. López-Sánchez^f, M. Sàbat^g, S. Segura^h, D. Bodetⁱ, N. Curcó^j, D. Lopez-Castillo^k, J. Solà^l, M. Quintana-Codina^m, C. Baliu-Piquéⁿ, M. Just-Sarobé^o, S. Martín-Sala^p, J. Malveyh^c, S. Puig^c, C. Carrera^{c,q,2}, R.M. Martí^{a,r,2}, Network of Melanoma Centers in Catalonia

^a Department of Dermatology, Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili, Reus, Catalonia, Spain

^b Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Catalonia, Spain

^c Department of Dermatology, Hospital Clínic Barcelona, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain

^d Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain

^e Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain

^f Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IIB SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

^g Department of Dermatology, Hospital Universitari Parc Taulí, Sabadell, Catalonia, Spain

^h Department of Dermatology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain

ⁱ Department of Dermatology, Hospital Universitari Vall d'Hebrón, Barcelona, Catalonia, Spain

^j Department of Dermatology, Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain

^k Department of Dermatology, Hospital Moises Broggi, Sant Joan Despí, Catalonia, Spain

^l Department of Dermatology, Hospital General de Granollers, Granollers, Catalonia, Spain

^m Department of Dermatology, Hospital Universitari Sagrat Cor, Grupo Quironsalud, Barcelona, Catalonia, Spain

ⁿ Department of Dermatology, Hospital Universitari d'Igualada, Igualada, Catalonia, Spain

^o Department of Dermatology, Hospital Universitari Joan XXIII, Tarragona, Catalonia, Spain

^p Department of Dermatology, Hospital Dos de Maig, Barcelona, Catalonia, Spain

^q Centros de Investigación en Red de Enfermedades Raras (CIBERER) Instituto de Salud Carlos III, Spain

^r Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

Received 10 August 2024; accepted 9 October 2024

* Corresponding author.

E-mail address: joan.an.ba@gmail.com (J. Angel-Baldo).

¹ These authors contributed equally and should be considered the lead authors.

² Senior authors.

<https://doi.org/10.1016/j.ad.2024.10.060>

0001-7310/© 2025 Published by Elsevier España, S.L.U. on behalf of AEDV. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: J. Angel-Baldo, S. Podlipnik, A. Azón et al., Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.10.060>

KEYWORDS

Acral melanoma;
Risk factor;
Prognostic factor;
Cutaneous
melanoma;
Survival analysis;
Foot melanoma;
Hand melanoma

PALABRAS CLAVE

Melanoma acral;
Factor de riesgo;
Factor pronóstico;
Melanoma cutáneo;
Análisis de
supervivencia;
Melanoma de pie;
Melanoma de mano

Abstract

Q2 Background: Acral melanoma is associated with poor prognosis. Studying the characteristics and prognosis of Caucasian patients is crucial to understand the distinct features of this tumor. **Objectives:** To analyze the epidemiological, clinicopathological, and prognostic features of acral melanoma in Caucasian patients.

Methods: We conducted a retrospective, multicenter, cohort study of acral melanoma from a database across 20 hospitals from South Europe from January 2000 to December 2019.

Results: A total of 733 acral melanomas were identified (median age, 67.5 years; 95.2%, Caucasians; 77.5% of which were located on the feet). Overall, 77.5% of cases were invasive melanomas. Foot melanomas had a higher proportion of invasive cases (80.8% vs 69.8%; $p=0.003$), stages III and IV at diagnosis (24.8% vs 11.7%; $p<0.001$), thicker Breslow depth (2.8 mm vs 2.0 mm; $p=0.021$) and a higher rate of positive sentinel lymph node biopsy (SLNB) (30.7% vs 15.7%; $p=0.012$). Thicker Breslow depth and later age of onset were risk factors for melanoma-specific survival. Thicker Breslow depth and ulceration were independent prognostic factors of relapse-free survival. Melanoma location and histopathological subtype were not associated with worse prognosis. Recurrences were a common finding (27.7%), with distant metastases appearing earlier than locoregional recurrences (1.32 years [IQR, 1.12–1.87] vs 2.14 years [IQR, 1.68–2.70]; $p=0.015$).

Conclusion: This study, the largest in a predominantly Caucasian population, underscores the unfavorable outcomes of acral melanoma. Foot melanomas exhibited delayed detection, increased invasiveness, thicker Breslow depth, increased SLNB involvement, and higher AJCC stages. The high recurrence rate and early distant metastases emphasize the critical role of intensive follow-up and routine imaging modalities to detect asymptomatic relapses.

© 2025 Published by Elsevier España, S.L.U. on behalf of AEDV. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Melanoma acral en población caucásica: estudio de cohorte sobre factores epidemiológicos, clinicopatológicos y pronósticos

Resumen

Introducción: El melanoma acral está asociado con un pronóstico desfavorable. El estudio sobre las características y el pronóstico en los pacientes caucásicos puede ser crucial para comprender las características distintivas de este tumor.

Objetivos: Analizar las características epidemiológicas, clinicopatológicas y pronósticas del melanoma acral en los pacientes caucásicos.

Material y métodos: Estudio de cohorte retrospectivo de melanoma acral a partir de una base de datos multi-institucional en 20 hospitales españoles, entre enero de 2000 y diciembre de 2019.

Resultados: Se identificaron un total de 733 melanomas acrales (edad media: 67,5 años, el 95,2% caucásicos y el 77,5% en los pies). En general, el 77,5% de los casos fueron invasivos. Los melanomas localizados en los pies tuvieron una mayor proporción de casos invasivos (80,8 vs. 69,8%; $p=0,003$), estadios III y IV al diagnóstico (24,8 vs. 11,7%; $p<0,001$), valores de Breslow más altos (2,8 vs. 2,0 mm; $p=0,021$) y una mayor tasa de biopsia selectiva del ganglio centinela (BSGC) (30,7 vs. 15,7%; $p=0,012$). Un mayor grosor de Breslow y una edad de aparición más tardía fueron factores de riesgo para la supervivencia específica del melanoma. Un mayor grosor de Breslow y la ulceración fueron los factores pronósticos independientes para la supervivencia libre de recaída. La localización del melanoma y el subtipo histopatológico no se asociaron con un peor pronóstico. Las recurrencias fueron frecuentes (27,7%), con metástasis distantes apareciendo antes que las recurrencias locorregionales (1,32 años [IQR: 1,12-1,87] vs. 2,14 años [IQR: 1,68-2,70]; $p=0,015$).

Conclusión: Este estudio, el mayor en una población predominantemente caucásica, subraya los resultados desfavorables del melanoma acral. Los melanomas en los pies mostraron una detección tardía, mayor proporción de melanomas invasivos, valores de Breslow más profundos, mayor implicación de BSGC y estadios AJCC más altos. La alta tasa de recurrencia y las metástasis distantes tempranas enfatizan el papel crítico del seguimiento intensivo y las pruebas de imagen rutinarias para detectar recaídas asintomáticas.

© 2025 Publicado por Elsevier España, S.L.U. en nombre de AEDV. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Acral melanoma affects all populations worldwide and is recognized as a distinct melanoma subgroup due to its unique characteristics including epidemiological, clinicopathological, molecular and prognostic features.^{1–8}

According to the World Health Organization (WHO), acral melanoma are those occurring on the glabrous (non-hair-bearing) skin of the volar aspects of the fingers and toes, palms, soles, and nail beds.⁸ In addition, acral lentiginous melanoma (ALM) is a histopathological subtype of melanoma, characterized by specific morphological features as well.^{8–10}

Acral melanoma is clearly associated with poorer prognosis vs cutaneous melanoma found in other locations.^{1,2,6,8,10,11} This adverse prognosis has been attributed to several factors, such as thicker Breslow depth and more advanced stages, which could be attributed to delayed diagnosis in part due to older age and non-visible anatomic locations, but also to a more aggressive behavior of the histopathological subtype or molecular background on non-sun exposed areas.^{1,2,4,6,8,10–12}

In the present study, we used a large series of acral melanoma cases from a Southern European multicentre melanoma network over two decades to assess the epidemiological, clinicopathological and prognostic characteristics focusing on melanoma location, and analyze the recurrence patterns, melanoma-specific survival (MSS) and relapse-free survival (RFS) which can influence the follow-up and management of patients with acral melanoma.

Materials and methods

The Network of Melanoma Centers in Catalonia database (*Xarxa Melanoma Catalunya*),^{13–15} a collaborative, prospective, multicenter database project including more than 20 hospitals from Northeast Spain was used to perform a retrospective study of patients with acral melanoma from January 2000 to December 2019 and followed up until August 2023.

All patients diagnosed with melanoma on acral sites with confirmed and properly registered melanoma diagnosed at these centers were initially considered to be included in the study. Data collection and analysis of all patients were approved under the protocol reference No. (HCB IRB; approval #2015/0298). Cases that were not consistent with the WHO definition of acral melanoma were excluded, keeping only those localized on the glabrous skin of hands and feet, including the nail apparatus. Cases were also excluded when location was not concordant, or when poorly defined.

The main variable used to analyze data was the anatomical location between hand and foot. Information on demographics, melanoma attributes, and prognostic data were recorded. Variables analyzed included gender, age at diagnosis, race and number of primary melanomas. Melanoma features included location (foot vs hand); stage (in situ vs invasive), staging according to the American Joint Committee on Cancer (AJCC) 8th edition, histopathological subtype (ALM, superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nodular melanoma [NM] and other subtypes), Breslow depth, presence of mitotic figures, ulceration, associated nevi and satellitosis, sentinel

lymph node biopsy (SLNB) performance and status. Prognostic data included recurrence patterns: timing and location (locoregional [lymph node or in-transit/satellitosis] and distant organs). Survival analysis was performed using 5-year and across the years MSS and RFS using the Kaplan–Meier method. Melanoma-related deaths were determined based on the patients’ death certificates and clinical history. MSS alludes to the time from melanoma excision to the date of death directly attributed to the disease. RFS alludes to the period from melanoma excision to disease detection in patients who had no residual disease after surgical procedures.

Statistical analysis

The frequencies and percentages were used to portray the distributions of categorical variables, while the distributions of continuous variables were expressed as median and interquartile range (IQR). The analysis of categorical variables included the Chi-squared test, or Fisher’s exact test when any expected cell count was <5. Meanwhile, ordinal variables were expressed using the trend test. In the context of comparing independent continuous variables, the Wilcoxon rank sum test was employed.

The cohort median follow-up was estimated using the reverse Kaplan–Meier estimator. This estimate was conducted by applying the *prodlim* package (version 2023.3.31) in R, using both *prodlim* and *Hist* functions.

We conducted univariate and multivariate survival analyses, presenting HRs with 95% confidence intervals from fitted Cox proportional hazard models. These models were created using the *coxph* function in the survival software package (version 3.5.5) in R. Hazard ratios (HRs) were estimated for acral melanoma location (feet vs hands), independently adjusted for age at diagnosis, gender, Breslow Index, ulceration, and histological subtype. A concise Cox regression table showed both univariate and multivariate hazard ratios for improved data visualization.

Within the metastatic patient subgroup, we evaluated the relapse timing of acral melanomas using a cumulative event plot, calculating the median survival time. Additionally, we used Sankey plots as a powerful visual tool to depict the first metastatic locations of acral melanoma patients. Furthermore, we performed computations to ascertain the proportions of patients in each group with disease progression.

All statistical analyses were performed using the computing environment R version 4.3.1 (2023-06-16) and RStudio (version 2023.6.1.524). *p* values < 0.05 were considered statistically significant.

Results

A total of 906 patients were identified out of 19,951 registered in the regional database (Network of Melanoma Centers of Catalonia). After per-protocol exclusions (melanomas located on non-glabrous skin of hands and feet, or locations not concordant-poorly defined), the number of total acral melanomas of this study were 733 from a total of 730 patients. The median follow-up time of the cohort calcu-

Table 1 Demographic and histopathological features of all melanomas.

Variable	Overall, N = 733	Location		p-Value ¹
		Foot, N = 568	Hand, N = 165	
Gender, n (%)				0.645
Female	429 (58.5%)	335 (59.0%)	94 (57.0%)	
Male	304 (41.5%)	233 (41.0%)	71 (43.0%)	
Age, median (IQR)	67.5 (53.7–78.6)	67.8 (53.9–79.4)	65.7 (53.2–76.2)	0.099
Race, n (%)				0.371
White	338 (95.2%)	266 (96.0%)	72 (92.3%)	
Latin	8 (2.3%)	5 (1.8%)	3 (3.8%)	
Asian	4 (1.1%)	2 (0.7%)	2 (2.6%)	
Indian	2 (0.6%)	1 (0.4%)	1 (1.3%)	
Gipsy	1 (0.3%)	1 (0.4%)	0 (0.0%)	
Black	1 (0.3%)	1 (0.4%)	0 (0.0%)	
Missing	379	292	87	
Staging, n (%)				0.003
In situ	157 (21.7%)	108 (19.2%)	49 (30.2%)	
Invasive	568 (78.3%)	455 (80.8%)	113 (69.8%)	
Missing	8	5	3	
AJCC 2017, n (%)				<0.001
0	156 (21.5%)	107 (19.0%)	49 (30.2%)	
I	186 (25.7%)	139 (24.7%)	47 (29.0%)	
II	224 (30.9%)	177 (31.4%)	47 (29.0%)	
III	145 (20.0%)	128 (22.7%)	17 (10.5%)	
IV	14 (1.9%)	12 (2.1%)	2 (1.2%)	
Missing	8	5	3	
Number of primary melanomas, n (%)				0.189
Multiple primary melanomas	42 (5.7%)	36 (6.3%)	6 (3.6%)	
Single primary melanoma	691 (94.3%)	532 (93.7%)	159 (96.4%)	
Associated nevus, n (%)				<0.001
De novo melanoma	363 (87.7%)	265 (84.1%)	98 (99.0%)	
Nevus-associated melanoma	51 (12.3%)	50 (15.9%)	1 (1.0%)	
Missing	319	253	66	
Histological subtype, n (%)				0.030
Acral lentiginous	666 (90.9%)	509 (89.6%)	157 (95.2%)	
Nodular	67 (9.1%)	59 (10.4%)	8 (4.8%)	

Data expressed as No. (%) unless otherwise indicated.

IQR, Interquartil range; AJCC, American Joint Committee on Cancer;

¹ Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test.

lated with the reverse Kaplan–Meier methods was 8.34 years with an IQR, of 4.89–13.01 years.

Demographic and histopathological features

The demographic and histopathological features of all melanomas are shown in Table 1. The features of invasive melanomas (N = 568, 77.5%) are shown in Table 2. Overall, median age was 67.5 years (IQR, 53.7–78.6; 58.5%, women). The anatomic distribution of the tumors was 568 on the feet (77.5%) and 165 on the hands (22.5%). A total of 95% of the patients were Caucasian.

Considering the whole series, all cases were histopathologically categorized as ALM (N = 666, 90.9%) and NM (N = 67, 9.1%), with the foot melanoma group having more NM (10.4% vs 4.8%; p = 0.030). The hand melanoma group had more in situ and stage I cases (59.2% vs 43.7% on feet; p < 0.001), while the foot melanoma group had more advanced cases at diagnosis (stages III and IV) (24.8% vs 11.7%; p < 0.001). Significant differences were observed regarding the number of invasive cases when foot and hand tumors were compared (80.8% vs 69.8%, respectively; p = 0.003). Overall, 42 patients (5.7%) exhibited multiple primary melanomas, while only 3 patients of this cohort developed > 1 acral

Table 2 Demographic and histopathological features of invasive melanomas.

Variable	Overall, N = 568	Location		p-Value ¹
		Foot, N = 455	Hand, N = 113	
<i>Gender, n (%)</i>				0.573
Female	315 (55.5%)	255 (56.0%)	60 (53.1%)	
Male	253 (44.5%)	200 (44.0%)	53 (46.9%)	
<i>Age, median (IQR)</i>	69.5 (56.4–79.4)	70.5 (56.4–79.9)	68.8 (56.6–77.7)	0.375
<i>AJCC 2017, n (%)</i>				0.014
I	185 (32.6%)	138 (30.3%)	47 (41.6%)	
II	224 (39.4%)	177 (38.9%)	47 (41.6%)	
III	145 (25.5%)	128 (28.1%)	17 (15.0%)	
IV	14 (2.5%)	12 (2.6%)	2 (1.8%)	
<i>Number of primaries melanomas, n (%)</i>				0.854
Multiple primary melanomas	27 (4.8%)	22 (4.8%)	5 (4.4%)	
Single primary melanoma	541 (95.2%)	433 (95.2%)	108 (95.6%)	
<i>Breslow, median (IQR)</i>	2.7 (1.3–5.0)	2.8 (1.3–5.0)	2.0 (1.0–4.2)	0.021
Missing	5	4	1	
<i>Ulceration, n (%)</i>				0.109
Absent	290 (52.3%)	225 (50.6%)	65 (59.1%)	
Present	265 (47.7%)	220 (49.4%)	45 (40.9%)	
Missing	13	10	3	
<i>Mitotic index mm², n (%)</i>				0.743
≥1 mitosis	316 (73.5%)	254 (73.8%)	62 (72.1%)	
0 mitosis	114 (26.5%)	90 (26.2%)	24 (27.9%)	
Missing	138	111	27	
<i>Histological subtype, n (%)</i>				0.092
Acral lentiginous	502 (88.4%)	397 (87.3%)	105 (92.9%)	
Nodular	66 (11.6%)	58 (12.7%)	8 (7.1%)	
<i>Satellitosis, n (%)</i>				0.096
Absent	541 (95.2%)	430 (94.5%)	111 (98.2%)	
Present	27 (4.8%)	25 (5.5%)	2 (1.8%)	
<i>Associated nevus, n (%)</i>				0.011
De novo melanoma	307 (91.4%)	233 (89.3%)	74 (98.7%)	
Nevus-associated melanoma	29 (8.6%)	28 (10.7%)	1 (1.3%)	
Missing	232	194	38	
<i>Sentinel lymph node biopsy, n (%)</i>				0.256
Direct lymphadenectomy	17 (3.2%)	16 (3.8%)	1 (0.9%)	
Not indicated	102 (19.2%)	76 (17.9%)	26 (24.3%)	
SLNB not performed	94 (17.7%)	77 (18.1%)	17 (15.9%)	
SLNB performed	319 (60.0%)	256 (60.2%)	63 (58.9%)	
Missing	36	30	6	
<i>Sentinel lymph node biopsy status, n (%)</i>				0.012
Affected	93 (27.6%)	82 (30.7%)	11 (15.7%)	
Not affected	244 (72.4%)	185 (69.3%)	59 (84.3%)	
Missing	231	188	43	

Data are expressed as No. (%) unless otherwise indicated; IQR, interquartil range; AJCC, American Joint Committee on Cancer.

¹ Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test.




Figure 1 Kaplan-Meier curves for melanoma-specific survival (A) and relapse-free survival (B).

225 melanoma. Moreover, foot melanomas had a higher percent-
226 age of nevus-associated melanoma vs the hand melanoma
227 group (15.9% vs .01%; $p < 0.001$).

228 Histopathological features of invasive melanomas

229 Regarding invasive melanomas, the hand melanoma group
had a higher percentage of stage I and II melanomas (83.2%

vs 69.2%; $p = 0.014$). Median Breslow of the series was 2.7 mm
(IQR, 1.3–5.0) with the foot melanoma group having thicker
Breslow depth [2.8 mm (IQR, 1.3–5.0) vs 2.0 mm (IQR,
1.0–4.2); $p = 0.021$]. Ulceration was present in 47.7% of
all cases; no significant differences were detected between
hand and foot acral melanoma. The distribution of the his-
tological subtypes was 88.4% for ALM and 11.6% for NM,
with no differences being reported between hand and foot

230
231
232
233
234
235
236
237

acral melanoma. Foot melanomas had a higher percentage of nevus-associated melanoma vs the hand melanoma group (10.7% vs 1.3%; $p=0.011$). Regarding stage III patients, we observed that 93 patients (64.1%) were diagnosed via SLNB and 52 cases (35.9%) via visible locoregional disease at the time of diagnosis. SLNB was performed in 319 cases (60%) with affected status in 93 cases (27.6%). A statistically significant difference in SLNB status was observed with a higher number of positive SLNB in the foot melanoma group (30.7% vs 15.7%; $p=0.012$).

Survival analysis

Overall, the 5-year MSS rate was 71.5% (95%CI, 67.4–75.8). These survival rates were 69.1% (95%CI, 64.6–74.0) for the foot group and 81.2% (95%CI, 73.1–90.2) for the hand melanoma group. Overall, the 5-year RFS rate was 61.8% (95%CI, 57.5–66.5); 59.5% (95%CI, 54.6–64.8) for the foot group and 70.9% (95%CI, 61.4–81.6) for the hand melanoma group. The Kaplan–Meier curves showed that foot melanomas had statistically significant lower MSS ($p=0.019$) and RFS rates ($p=0.011$) vs hand melanomas. In this series, no patients with in situ melanoma died of melanoma-related deaths. The results are shown in Fig. 1.

Univariate Cox logistic regression analysis of MSS showed that foot location of melanoma, later age of onset, male gender, thicker Breslow depth, presence of ulceration and nodular melanoma subtype were associated with worse prognosis.

The multivariate Cox logistic regression analysis confirmed that later age of onset (>75 years; HR, 1.61; 95%CI, 1.05–2.46; $p=0.030$), and thicker Breslow depth (>1.0–2 mm; HR, 5.85; 95%CI, 1.76–19.45; $p=0.004$; >2.0–4 mm; HR, 11.18; 95%CI, 3.41–36.70; $p<0.001$; >4 mm; HR, 14.20; 95%CI, 4.28–47.06; $p<0.001$) were independent predictors of worse MSS.

Regarding RFS, the overall 5-year RFS rate was 61.8% (95%CI, 57.5–66.5) with 5-year RFS rates of 59.5% (95%CI, 54.6–64.8) for the foot group and 70.9% (95%CI, 61.6–81.6) for the hand melanoma group. Univariate Cox logistic regression analysis showed that foot location of melanoma, thicker Breslow depth, presence of ulceration and nodular melanoma subtype were associated with worse RFS. Nevertheless, multivariate regression models found that only Breslow depth (>1.0–2 mm; HR, 3.91; 95%CI, 1.62–9.45; $p=0.002$; >2.0–4 mm; HR, 7.68; 95%CI, 3.23–18.29; $p<0.001$; >4 mm; HR, 10.12; 95%CI, 4.19–24.41; $p<0.001$) and the presence of ulceration (HR, 1.57, 95%CI 1.11–2.22; $p=0.011$) were independent risk factors of RFS.

Data associated with univariate and multivariate Cox regression models for MSS and RFS are shown in Table 3.

For the recurrence pattern, the median time to the index metastasis was 1.74 years (IQR, 1.48–2.17) (Fig. 2). Most patients (81.7%) who recurred developed the first metastasis within the first 4 years of follow-up.

A total of 202 patients (27.7%) developed recurrences after a mean follow-up of 100 months. The most common site of relapse was locoregional ($n=121$; 59.9%), while 81 patients (40.1%) developed distant metastases. For the location of the index metastasis, Kaplan–Meier curves showed

that distant metastases appeared earlier than locoregional metastases did (median time, 1.32 years (IQR, 1.12–1.87) vs 2.14 years (IQR, 1.68–2.70); $p=0.015$) (Fig. 2). Most distant metastases were pulmonary (34.6%), followed by hepatic (13.6%), associated with the central nervous system (12.3%), and distant lymphatic (12.3%) metastases. The distribution of the index metastases is illustrated in Fig. 3.

Discussion

As far as we know, the present 20-year retrospective study of acral melanoma in Europe is the largest series ever conducted in a predominantly white population.

Melanoma on the acral regions affects all populations worldwide. However, represents a significant number of cases (20% up to 70%) in countries with a lower incidence of sun-related melanoma, such as those in Asian, African, and Latin American regions.^{8,16–19} Given its importance, most studies on acral melanoma focus on non-Caucasian populations.

Acral melanoma is a rare entity with distinctive peculiarities associated with poorer prognosis vs cutaneous melanoma found in different locations.^{2,6,10,11,20,21} This adverse prognosis has been attributed to several factors, as mentioned. In our cohort, a significant number of cases were diagnosed with thicker Breslow depth, high prevalence of ulceration and advanced stages, as most studies reported.^{2,6,10–12,21,22} Notably, 21.9% of our cohort was diagnosed with non-localized AJCC 8th edition stage disease (stage III and IV), which is consistent with other series.^{6,21,23} This percentage of non-localized stages is considerably higher than that of the series of non-acral melanomas.¹¹ Moreover, acral melanoma is associated with older age and most cases occurred on the feet, as we have already seen.^{2,6,10–12,20,22,24} These findings collectively suggest a notable delay in diagnosis, predominantly attributed to the less conspicuous location of melanomas, such as the feet, a factor that is particularly pertinent in older populations, as proposed by other authors.^{2,4,10–15} Overall, about 20% up to 30% of melanomas are originated from a melanocytic nevus precursor.^{25–27} Nevus-associated melanomas have been associated with a younger age at diagnosis, higher nevus counts, thinner melanomas, and intermittently sun-exposed body locations such as the trunk. Histopathologically, they develop SSM and harbor *BRAF* mutations.^{25–27} It is remarkable that in our population the prevalence of nevus-associated melanomas was only 1% on the hand melanoma group and 16% on the foot melanoma group, which could be explained by the relatively older population of the cohort, the absence of SSM and the low incidence of *BRAF* mutations that acral melanomas tend to associate. Moreover, a few studies on ALM have indicated that melanomas tend to occur in areas of the hands and feet prone to mechanical stress.^{22,28–31} Pressure, trauma and physical stress on the feet could play a role in the pathogenesis of nevus-associated melanomas and explain the differences between hand and foot melanoma group.

Histological subtype and melanoma location have been a matter of discussion regarding their impact on prognosis. Some studies suggest that ALM or acral melanoma location are associated with a poorer prognosis^{2,6,10,11,20,21}

Table 3 Univariate and multivariate Cox regression analysis of melanoma-specific survival (MSS) and relapse-free survival (RFS).

	MSS		RFS	
	HR (univariable)	HR (multivariable)	HR (univariable)	HR (multivariable)
<i>Location</i>				
Foot	•	•	•	•
Hand	0.59 (0.37–0.92, <i>p</i> = 0.020)	0.70 (0.44–1.12, <i>p</i> = 0.139)	0.59 (0.39–0.89, <i>p</i> = 0.012)	0.72 (0.47–1.09, <i>p</i> = 0.119)
<i>Age (tertiles)</i>				
<58.3	•	•	•	•
58.3–75	1.64 (1.08–2.48, <i>p</i> = 0.019)	1.43 (0.94–2.18, <i>p</i> = 0.099)	1.29 (0.90–1.86, <i>p</i> = 0.166)	1.03 (0.71–1.49, <i>p</i> = 0.882)
>75	2.02 (1.33–3.06, <i>p</i> = 0.001)	1.61 (1.05–2.46, <i>p</i> = 0.030)	1.40 (0.96–2.02, <i>p</i> = 0.077)	1.17 (0.81–1.70, <i>p</i> = 0.410)
<i>Gender</i>				
Female	•	•	•	•
Male	1.58 (1.17–2.15, <i>p</i> = 0.003)	1.28 (0.94–1.76, <i>p</i> = 0.122)	1.29 (0.97–1.72, <i>p</i> = 0.075)	1.03 (0.77–1.39, <i>p</i> = 0.819)
<i>Breslow depth</i>				
≤1.0 mm	•	•	•	•
>1.0–2 mm	5.31 (1.85–15.21, <i>p</i> = 0.002)	5.85 (1.76–19.45, <i>p</i> = 0.004)	3.41 (1.57–7.41, <i>p</i> = 0.002)	3.91 (1.62–9.45, <i>p</i> = 0.002)
>2.0–4 mm	11.95 (4.32–33.10, <i>p</i> < 0.001)	11.18 (3.41–36.70, <i>p</i> < 0.001)	7.81 (3.74–16.31, <i>p</i> < 0.001)	7.68 (3.23–18.29, <i>p</i> < 0.001)
>4 mm	17.77 (6.51–48.50, <i>p</i> < 0.001)	14.20 (4.28–47.06, <i>p</i> < 0.001)	11.44 (5.54–23.61, <i>p</i> < 0.001)	10.12 (4.19–24.41, <i>p</i> < 0.001)
<i>Ulceration</i>				
Absent	•	•	•	•
Present	2.94 (2.11–4.10, <i>p</i> < 0.001)	1.37 (0.94–1.99, <i>p</i> = 0.100)	3.14 (2.31–4.27, <i>p</i> < 0.001)	1.57 (1.11–2.22, <i>p</i> = 0.011)
<i>Histological subtype</i>				
Acral lentiginous	•	•	•	•
Nodular	2.08 (1.42–3.07, <i>p</i> < 0.001)	1.22 (0.81–1.84, <i>p</i> = 0.348)	1.52 (1.02–2.27, <i>p</i> = 0.040)	0.86 (0.57–1.31, <i>p</i> = 0.490)

HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; pT, pathological; T, tumor

356 while other indicate that their prognosis is similar to that
357 of other melanoma subtypes and locations.^{4,12,22–24,32,33} In
358 our series, when comparing hands vs feet melanomas, we
359 observed that melanomas on the feet exhibited thicker Bres-
360 low depths, more prevalent SLNB involvement, and higher
361 AJCC 8th edition stages. However, the location of melanoma
362 and its histopathological subtype were not associated with
363 poorer prognosis in terms of MSS or RFS. Thicker Breslow
364 depth and later age of onset (>75 years) were the only
365 independent prognostic factors for MSS, while thicker Bres-
366 low depth and ulceration were independent risk factors for
367 RFS.

368 Former studies suggest that there could be differ-
369 ences in the dynamics of metastatic spread between acral
370 and non-acral melanoma, particularly in terms of higher
371 rates of both recurrence and distant metastases in acral
372 melanoma.^{2,6,10,12,34–43} Moreover, it has been reported that
373 risk factors for lymphatic or hematogenous metastases may
374 vary,^{44,45} where thicker Breslow depths have been reported
375 as a predictor for hematogenous metastases.⁴⁵ Furthermore,
376 patients with earlier stages developed relapses later than

377 those with more advanced stages, which was clearly marked
378 in distant metastasis.^{42,46,47} In our research, we observed
379 a high rate of melanoma relapses with predominance of
380 locoregional metastases; however, a significant proportion
381 of cases also developed distant metastases. Notably, distant
382 metastases showed earlier than locoregional metastases and
383 did so in a shorter period of time vs other series published
384 to this date,^{42,48–50} which could be explained by the thick
385 Breslow depths reported in the study leading to a major
386 risk for distant and earlier metastasis. As far as we know,
387 there are no other specific studies on this phenomenon in
388 acral melanoma series. These observations underscore the
389 complexity and variability of the metastatic behaviour of
390 melanomas and highlight the importance of considering rou-
391 tine imaging modalities to detect asymptomatic recurrences
392 or metastases 3–5 years after diagnosis, depending on the
393 risk of relapse, according to the National Comprehensive
394 Cancer Network (NCCN) guidelines.⁵¹

395 This study has the limitations inherent to its retrospective
396 design. However, data were prospective and multicentric-
397 ally collected. There are missing values in significant data




Figure 2 Recurrence patterns. Kaplan–Meier curves time to index metastasis (A) and type of index metastasis (B). Sankey plot of the distribution of metastases (C).

398 points, such as the exact location on acral zones, the socioe-
399 conomic factors, the genetic testing of the tumors, and the
400 margins obtained in melanoma-related surgical procedures.
401 In the case of recurrences, we did not explore whether
402 these patients developed synchronous metastases or sub-

sequent distant metastases in patients initially presenting
with locoregional metastases. Due to the heterogeneity of
surgical procedures and systemic therapies throughout 2
decades, we did not delve into the outcomes based on the
therapies received.

403
404
405
406
407




Figure 3 Sankey plot showing the distribution of index metastases.

408 In conclusion, we present the largest study ever conducted on acral melanomas in a predominantly Caucasian population. A significant number of cases were diagnosed with thick Breslow depth, high prevalence of ulceration, advanced stages and low prevalence of nevus-associated melanomas. Melanomas originating on the feet were later detected—were more associated with nevus—had a higher proportion of nodular subtype, and more advanced AJCC 8th edition stages vs those arising on the hand. Thicker Breslow depth and later age of onset were independent prognostic factors for MSS, while thicker Breslow depth and ulceration were independent risk factors for RFS. Melanoma location and histopathological subtype were not associated with a poorer prognosis. Recurrences were a common finding, with distant metastases appearing earlier than locoregional recurrences, which highlights the importance of intensive follow-up and routine imaging modalities to monitor asymptomatic recurrences.

Conflict of interests

Q3 The authors state that they have no conflict of interests.

References

1. Carrera C, Puig-Butille JA. Clinical, epidemiological, and molecular heterogeneity in acral melanoma. *J Invest Dermatol.* 2018;138:254–5, <http://dx.doi.org/10.1016/j.jid.2017.09.027>. 427-431
2. Carrera C, Gual A, Díaz A, et al. Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians. *Melanoma Res.* 2017;27:315–20, <http://dx.doi.org/10.1097/CMR.0000000000000340>. 432-435
3. Haugh AM, Zhang B, Quan VL, et al. Distinct patterns of acral melanoma based on site and relative sun exposure. *J Invest Dermatol.* 2018;138:384–93, <http://dx.doi.org/10.1016/j.jid.2017.08.022>. 436-439
4. Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. *Br J Dermatol.* 2018;178:443–51, <http://dx.doi.org/10.1111/bjd.15803>. 440-444
5. Cho KK, Cust AE, Foo YM, Long GV, Menzies AM, Eslick GD. Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. *Melanoma Res.* 2021;31:482–6, <http://dx.doi.org/10.1097/CMR.0000000000000764>. 445-447

- 448 6. Kolla AM, Vitiello GA, Friedman EB, et al. Acral lentig- 513
449 inous melanoma: a United States multi-center substage 514
450 survival analysis. *Cancer Control*. 2021;28, [http://dx.doi.org/](http://dx.doi.org/10.1177/10732748211053567) 515
451 [10.1177/10732748211053567](http://dx.doi.org/10.1177/10732748211053567), 10732748211053567. 516
452 7. Bian SX, Hwang L, Hwang J, et al. Acral lentiginous melanoma- 517
453 population, treatment, and survival using the NCDB from 518
454 2004 to 2015. *Pigment Cell Melanoma Res*. 2021;34:1049-61, 519
455 <http://dx.doi.org/10.1111/pcmr.12999>. 520
456 8. Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. 521
457 The 2018 World Health Organization classification of 522
458 cutaneous, mucosal, and uveal melanoma: detailed 523
459 analysis of 9 distinct subtypes defined by their evolu- 524
460 tionary pathway. *Arch Pathol Lab Med*. 2020;144:500-22, 525
461 <http://dx.doi.org/10.5858/arpa.2019-0561-RA>. 526
462 9. Bernardes SS, Ferreira I, Elder DE, et al. More than just acral 527
463 melanoma: the controversies of defining the disease. *J Pathol* 528
464 *Clin Res*. 2021, <http://dx.doi.org/10.1002/cjp2.233>. Published 529
465 online July 2. 530
466 10. Rex J, Paradelo C, Mangas C, Hilari JM, Fernández- 531
467 Figueras MT, Ferrándiz C. Management of primary 532
468 cutaneous melanoma of the hands and feet: a clin- 533
469 icoprognostic study. *Dermatol Surg*. 2009;35:1505-13, 534
470 <http://dx.doi.org/10.1111/j.1524-4725.2009.01265.x>. 535
471 11. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral 536
472 lentiginous melanoma: incidence and survival patterns in the 537
473 United States, 1986-2005. *Arch Dermatol*. 2009;145:427-34, 538
474 <http://dx.doi.org/10.1001/archdermatol.2008.609>. 539
475 12. Boriani F, O'Leary F, Tohill M, Orlando A. Acral Lentiginous 540
476 Melanoma - misdiagnosis, referral delay and 5 years spec- 541
477 ific survival according to site. *Eur Rev Med Pharmacol Sci*. 542
478 2014;18:1990-6. 543
479 13. Puig S, Marcoval J, Paradelo C, et al. Melanoma inci- 544
480 dence increases in the elderly of Catalonia but not in 545
481 the younger population: effect of prevention or conse- 546
482 quence of immigration? *Acta Derm Venereol*. 2015;95:422-6, 547
483 <http://dx.doi.org/10.2340/00015555-1997>. 548
484 14. Podlipnik S, Carrera C, Boada A, et al. Incidence of melanoma 549
485 in Catalonia, Spain, is rapidly increasing in the elderly popu- 550
486 lation. A multicentric cohort study. *J Clin Med*. 2020;9:3396, 551
487 <http://dx.doi.org/10.3390/jcm9113396>. 552
488 15. Segura S, Podlipnik S, Boada A, et al. Melanoma-specific 553
489 survival is worse in the elderly: a multicen- 554
490 tric cohort study. *Melanoma Res*. 2023;33:532-8, 555
491 <http://dx.doi.org/10.1097/CMR.0000000000000923>. 556
492 16. Hudson DA, Krige JE. Melanoma in black South Africans. *J Am* 557
493 *Coll Surg*. 1995;180:65-71. 558
494 17. Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, 559
495 and prognoses of malignant melanoma in ethnic Chinese: 560
496 a study of 522 consecutive cases. *BMC Cancer*. 2011;11:85, 561
497 <http://dx.doi.org/10.1186/1471-2407-11-85>. 562
498 18. Lee HY, Chay WY, Tang MB, Chio MT, Tan SH. Melanoma: dif- 563
499 ferences between Asian and Caucasian patients. *Ann Acad Med* 564
500 *Singap*. 2012;41:17-20. 565
501 19. Quintella Mendes GL, Koifman S. Socioeconomic statu- 566
502 s as a predictor of melanoma survival in a series of 567
503 1083 cases from Brazil: just a marker of health ser- 568
504 vices accessibility? *Melanoma Res*. 2013;23:199-205, 569
505 <http://dx.doi.org/10.1097/CMR.0b013e32835e76f8>. 570
506 20. Mejbel HA, Torres-Cabala CA, Milton DR, et al. Prog- 571
507 nostic significance of acral lentiginous histologic 572
508 type in T1 melanoma. *Mod Pathol*. 2021;34:572-83, 573
509 <http://dx.doi.org/10.1038/s41379-020-0641-x>. 574
510 21. Bello DM, Chou JF, Panageas KS, et al. Prog- 575
511 nosis of acral melanoma: a series of 281 576
512 patients. *Ann Surg Oncol*. 2013;20:3618-25, 577
<http://dx.doi.org/10.1245/s10434-013-3089-0>. 578
22. Jung HJ, Kweon SS, Lee JB, Lee SC, Yun SJ. A 513
514 clinicopathologic analysis of 177 acral melanomas 515
516 in Koreans: relevance of spreading pattern and 517
518 physical stress. *JAMA Dermatol*. 2013;149:1281-8, 519
<http://dx.doi.org/10.1001/jamadermatol.2013.5853>. 520
23. Wada M, Ito T, Tsuji G, et al. Acral lentiginous melanoma versus 521
522 other melanoma: a single-center analysis in Japan. *J Dermatol*. 523
2017;44:932-8, <http://dx.doi.org/10.1111/1346-8138.13834>. 524
24. Paolino G, Bekkenk MW, Didona D, et al. Is the prognosis and 525
526 course of acral melanoma related to site-specific clinicopatho- 527
528 logical features? *Eur Rev Med Pharmacol Sci*. 2016;20:842-8. 529
25. Bosch-Amate X, Podlipnik S, Riquelme-Mc Loughlin 530
531 C, et al. Clinicopathological, genetic and survival 532
533 advantages of naevus-associated melanomas: a cohort 534
535 study. *Acta Derm Venereol*. 2021;101:adv00425, 536
<http://dx.doi.org/10.2340/00015555-3780>. 537
26. Dessinioti C, Geller AC, Stratigos AJ. A review of 538
539 nevus-associated melanoma: what is the evidence? 540
541 *J Eur Acad Dermatol Venereol*. 2022;36:1927-36, 542
<http://dx.doi.org/10.1111/jdv.18453>. 543
27. Martín-Gorgojo A, Nagore E. Melanoma arising in a melanocytic 544
545 nevus. *Actas Dermosifiliogr (Engl Ed)*. 2018;109:123-32, 546
<http://dx.doi.org/10.1016/j.ad.2017.06.009>. 547
28. Lee JH, Choi YD, Hwang JH, Shin MH, Yun SJ. Fre- 548
549 quency of trauma, physical stress, and occupation in 549
550 acral melanoma: analysis of 313 acral melanoma 551
552 patients in Korea. *Ann Dermatol*. 2021;33:228-36, 553
<http://dx.doi.org/10.5021/ad.2021.33.3.228>. 554
29. Zhang N, Wang L, Zhu GN, et al. The association between 555
556 trauma and melanoma in the Chinese population: a retrospec- 557
558 tive study. *J Eur Acad Dermatol Venereol*. 2014;28:597-603, 559
<http://dx.doi.org/10.1111/jdv.12141>. 560
30. Arango Abisaad J, Arciniegas Grisales V, Londoño García Á, 561
562 Vasquez Trespalcacios EM, Jiménez Calfat G, Cuello López JM. 563
564 Characteristics of acral lentiginous melanoma according to 564
565 location in stress- or non-stress-bearing areas: a retrospective 566
567 study of 95 patients. *Actas Dermosifiliogr*. 2022;113:134-40, 567
<http://dx.doi.org/10.1016/j.ad.2021.08.006>. 568
31. Green A, McCredie M, MacKie R, et al. A case-control study 569
570 of melanomas of the soles and palms (Australia and Scotland). 570
571 *Cancer Causes Control*. 1999;10:21-5. 571
32. Tan KB, Moncrieff M, Thompson JF, et al. Subungual 572
573 melanoma: a study of 124 cases highlighting features of 572
574 early lesions, potential pitfalls in diagnosis, and guidelines 573
575 for histologic reporting. *Am J Surg Pathol*. 2007;31:1902, 574
<http://dx.doi.org/10.1097/PAS.0b013e318073c600>. 575
33. Mejbel HA, Torres-Cabala CA, Milton DR, et al. Prognostic 576
577 significance of subungual anatomic site in acral lentigi- 576
578 nous melanoma. *Arch Pathol Lab Med*. 2021;145:943-52, 577
<http://dx.doi.org/10.5858/arpa.2020-0308-OA>. 578
34. Borges de Barros Primo R, Brito Nobre A, Santos BN, et al. Impact 579
580 of clinical and histopathological characteristics on the disease- 579
581 free survival of stage I-II acral melanoma patients. *Int J Derma- 580
582 tology*. 2023;62:1281-8, <http://dx.doi.org/10.1111/ijd.16800>. 581
35. Mervic L. Time course and pattern of metas- 582
583 tasis of cutaneous melanoma differ between 582
584 men and women. *PLoS ONE*. 2012;7:e32955, 583
<http://dx.doi.org/10.1371/journal.pone.0032955>. 584
36. Tejera-Vaquero A, Barrera-Vigo MV, Fernández-Canedo I, 585
586 et al. Longitudinal study of different metastatic patterns in 585
587 the progression of cutaneous melanoma. *Actas Dermosifiliogr*. 586
2007;98:531-8. 587
37. Marcoval J, Ferreres JR, Martín C, et al. Patterns 588
589 of visceral metastasis in cutaneous melanoma: a 588
590 descriptive study. *Actas Dermosifiliogr*. 2013;104:593-7, 589
<http://dx.doi.org/10.1016/j.adengl.2012.12.006>. 590

- 578 38. von Schuckmann LA, Hughes MCB, Ghiasvand R, et al. Risk of melanoma recurrence after diagnosis of a high-
579 risk primary tumor. *JAMA Dermatol.* 2019;155:688–93,
580 <http://dx.doi.org/10.1001/jamadermatol.2019.0440>.
581
- 582 39. Hohnheiser AM, Gefeller O, Göhl J, Schuler G, Hohenberger W,
583 Merkel S. Malignant melanoma of the skin: long-term follow-
584 up and time to first recurrence. *World J Surg.* 2011;35:580–9,
585 <http://dx.doi.org/10.1007/s00268-010-0859-8>.
586
- 587 40. Meier F, Will S, Ellwanger U, et al. Metastatic path-
588 ways and time courses in the orderly progression of
589 cutaneous melanoma. *Br J Dermatol.* 2002;147:62–70,
590 <http://dx.doi.org/10.1046/j.1365-2133.2002.04867.x>.
591
- 592 41. Leiter U, Meier F, Schittek B, Garbe C. The natural
593 course of cutaneous melanoma. *J Surg Oncol.* 2004;86:172–8,
594 <http://dx.doi.org/10.1002/jso.20079>.
595
- 596 42. Ertekin SS, Podlipnik S, Riquelme-Mc Loughlin C, et al. Initial
597 stage of cutaneous primary melanoma plays a key role in the
598 pattern and timing of disease recurrence. *Acta Derm Venereol.*
599 2021;101, <http://dx.doi.org/10.2340/00015555-3832>,
600 adv00502.
601
- 602 43. Vallet A, Oriano B, Mortier L, et al. Association of
603 time from primary diagnosis to first distant relapse
604 of metastatic melanoma with progression of dis-
605 ease and survival. *JAMA Dermatol.* 2019;155:673–8,
606 <http://dx.doi.org/10.1001/jamadermatol.2019.0425>.
- 607 44. Calomarde-Rees L, García-Calatayud R, Requena
608 Caballero C, et al. Risk factors for lymphatic and
609 hematogenous dissemination in patients with stages I–II
610 cutaneous melanoma. *JAMA Dermatol.* 2019;155:679–87,
611 <http://dx.doi.org/10.1001/jamadermatol.2019.0069>.
- 612 45. Berghe AS, Cobzac G, Dindelegan G, et al. Risk fac-
613 tors for positive sentinel lymph node, lymphatic or
614 hematogenous dissemination over time in patients
615 with cutaneous melanoma. *Exp Ther Med.* 2021;22:730,
616 <http://dx.doi.org/10.3892/etm.2021.10162>.
617
- 618 46. Tas F, Erturk K. Relapse patterns in
619 patients with local and regional cutaneous
620 melanoma. *Clin Transl Oncol.* 2019;21:412–9,
621 <http://dx.doi.org/10.1007/s12094-018-1938-9>.
622
- 623 47. Baade PD, Whiteman DC, Janda M, et al. Long-term deaths from
624 melanoma according to tumor thickness at diagnosis. *Int J Can-
625 cer.* 2020;147:1391–6, <http://dx.doi.org/10.1002/ijc.32930>.
626
- 627 48. Tas F, Erturk K. Recurrence behavior in early-stage
628 cutaneous melanoma: pattern, timing, survival, and
629 influencing factors. *Melanoma Res.* 2017;27:134–9,
630 <http://dx.doi.org/10.1097/CMR.0000000000000332>.
631
- 632 49. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and
633 timing of first relapse in stage III melanoma patients: implica-
634 tions for follow-up guidelines. *J Clin Oncol.* 2010;28:3042–7,
635 <http://dx.doi.org/10.1200/JCO.2009.26.2063>.
636
- 637 50. Lee AY, Droppelmann N, Panageas KS, et al. Patterns
638 and timing of initial relapse in pathologic stage II
639 melanoma patients. *Ann Surg Oncol.* 2017;24:939–46,
640 <http://dx.doi.org/10.1245/s10434-016-5642-0>.
641
- 642 51. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous
643 melanoma, version 2.2019, NCCN Clinical Practice Guide-
644 lines in Oncology. *J Natl Compr Canc Netw.* 2019;17:367–402,
645 <http://dx.doi.org/10.6004/jnccn.2019.0018>.
646